Pharmacological considerations of antitubercular agents in children

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 161-175

  Goldman, Jennifer L ^a   Kearns, Gregory L ^b,c,d   Abdel Rahman, Susan M ^c,d  

^a Divisions of Infectious Diseases   (United States)

^b Department of Medical Research and ^*  (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052958045     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000324904     Document Type: Review

References (123)

1. Marais BJ, Gupta A, Starke JR, El-Sony A: Tuberculosis in women and children. Lancet 2010;375:2057-2059.
2. Mukherjee A, Lodha R, Kabra SK: Changing trends in childhood tuberculosis. Indian J Pediatr 2011;78:328-333.
3. Graham SM: Treatment of paediatric TB: Revised WHO guidelines. Paediatr Respir Rev 2011;12:22-26.
4. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology -drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-1167. (Pubitemid 37122329)
5. Thee S, Detjen AA, Wahn U, Magdorf K: Isoniazid pharmacokinetic studies of the 1960s: Considering a higher isoniazid dose in childhood tuberculosis. Scand J Infect Dis 2010;42:294-298.
6. Seth V, Beotra A, Seth SD, Semwal OP, Kabra S, Jain Y, Mukhopadhya S: Serum concentrations of rifampicin and isoniazid in tuberculosis. Indian Pediatr 1993;30:1091-1098. (Pubitemid 23296039)
7. Roy V, Gupta D, Gupta P, Sethi GR, Mishra TK: Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis. Int J Tuberc Lung Dis 2010;14:374-376.
8. Peloquin CA, Namdar R, Dodge AA, Nix DE: Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999;3:703-710. (Pubitemid 29378471)
9. Schaaf HS, Parkin DP, Seifart HI, Werely CJ, Hesseling PB, van Helden PD, Maritz JS, Donald PR: Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005;90:614-618. (Pubitemid 40780724)
10. Notterman DA, Nardi M, Saslow JG: Effect of dose formulation on isoniazid absorption in two young children. Pediatrics 1986;77:850-852. (Pubitemid 16066301)
11. Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP: Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: The influence of dosage and acetylation status. Pediatrics 1992;89:247-250.
12. Pariente-Khayat A, Rey E, Gendrel D, Vauzelle-Kervroedan F, Cremier O, d'Athis P, Badoual J, Olive G, Pons G: Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 1997;62:377-383. (Pubitemid 27475221)
13. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP: Trimodality of isoniazid elimination phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997;155:1717-1722. (Pubitemid 27216683)
14. Pariente-Khayat A, Pons G, Rey E, Richard MO, d'Athis P, Moran C, Badoual J, Olive G: Caffeine acetylator phenotyping during maturation in infants. Pediatr Res 1991;29:492-495.
15. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS: The influence of dose and Nacetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007;63:633-639. (Pubitemid 46911342)
16. Peloquin CA: Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-2183. (Pubitemid 35252827)
17. McIlleron H, Willemse M, Werely CJ, Hussey GD, Schaaf HS, Smith PJ, Donald PR: Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: Implications for international pediatric dosing guidelines. Clin Infect Dis 2009;48:1547-1553.
18. Nakajo MM, Rao M, Steiner P: Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J 1989;8:649-650. (Pubitemid 19227821)
19. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL: Concentrationdependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-3788. (Pubitemid 350057771)
20. Nahata MC, Morosco RS, Hipple TF: Effect of preparation method and storage on rifampin concentration in suspensions. Ann Pharmacother 1994;28:182-185. (Pubitemid 24073453)
21. Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL: Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther Drug Monit 1986;8:17-22. (Pubitemid 16166117)
22. Tan TQ, Mason EO, Ou CN, Kaplan SL: Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993;37:2401-2406. (Pubitemid 23324463)
23. Acocella G: Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-127.
24. Thee S, Detjen A, Wahn U, Magdorf K: Rifampicin serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2009;13:1106-1111.
25. Hussels H, Kroening U, Magdorf K: Ethambutol and rifampicin serum levels in children: Second report on the combined administration of ethambutol and rifampicin. Pneumonologie 1973;149:31-38.
26. McCracken GH, Ginsburg CM, Zweighaft TC, Clahsen J: Pharmacokinetics of rifampin in infants and children: Relevance to prophylaxis against Haemophilus influenzae type b disease. Pediatrics 1980;66:17-21. (Pubitemid 10033797)
27. Koup JR, Williams-Warren J, Weber A, Smith AL: Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther Drug Monit 1986;8:11-16. (Pubitemid 16166116)
28. Holdiness MR: Clinical pharmacokinetics of the antiberculosis drugs. Clin Pharmacokinet 1984;9:511-544.
29. Nahata MC, Fan-Harvard P, Barson WJ, Bartkowski HM, Kosnik EJ: Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur J Clin Pharmacol 1990;38:515-517. (Pubitemid 20181285)
30. Peloquin CA: Therapeutic drug monitoring: Principles and application in mycobacterial infections. Drug Ther 1992;22:31-36.
31. World Health Organization: Pharmacokinetic analyses of fixed-dose drug combinations for pediatric tuberculosis. 2009. http://www.who. int/selection-medicines/committees/expert/17/application/TB-Children.pdf (accessed January 3, 2011).
32. Blake MJ, Abdel-Rahman SM, Jacobs RF, Lowery NK, Sterling TR, Kearns GL: Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J 2006;25:405-409.
33. Marshall JD, Abdel-Rahman S, Johnson K, Kauffman RE, Kearns GL: Rifapentine pharmacokinetics in adolescents. Pediatr Infect Dis J 1999;18:882-888. (Pubitemid 29487508)
34. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P: Rifabutin for the treatment of newlydiagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin. Rifabutin Study Group. Tuberc Lung Dis 1994;75:341-347. (Pubitemid 24336530)
35. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, Blaschke TF: Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989;33:1237-1241. (Pubitemid 19191964)
36. Mycobutin -rifaputin capsules (package insert). New York, Pharmacia & Upjohn, 2010.
37. Skinner MH, Blaschke TF: Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-125.
38. Peloquin CA, Jaresko GS, Yong CL, Keung AC, Bulpitt AE, Jelliffe RW: Population pharmacokinetics modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997;41;2670-2679. (Pubitemid 27524738)
39. Thee S, Detjen A, Wahn U, Magdorf K: Pyrazinamide serum levels in childhood tuberculosis. Int J Tuberc Lung Dis 2008;12:1099-1101.
40. Gupta P, Roy V, Sethi GR, Mishra TK: Pyrazinamide blood concentrations in children suffering from tuberculosis: A comparative study at two doses. Br J Clin Pharmacol 2007;65:423-427. (Pubitemid 351316921)
41. Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, Lafont O: Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989;36:395-400. (Pubitemid 19140044)
42. Donald PR, Seifart H: Cerebrospinal fluid pyrazinamide concentrations in children with tuberculous meningitis. Pediatr Infect Dis J 1988;7:469-471.
43. Pyrazinamide tablets (package insert). Mumbai, Macleods Pharmaceuticals Ltd, 2007.
44. Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA, Molyneux EM: Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50:407-413. (Pubitemid 43190946)
45. Arya DS, Ojha SK, Semwal OP, Nandave M: Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. Indian J Med Res 2008;128:611-615.
46. Roy V, Tekur U, Chopra K: Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis 1999;3:133-137. (Pubitemid 29151816)
47. Zhu M, Starke JR, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA: Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002;22:686-695. (Pubitemid 34596476)
48. US Public Health Service: Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. Am Rev Respir Dis 1969;59:13.
49. Zhu M, Burman WJ, Starke JR, Stambaugh JJ, Steiner P, Bulpitt AE, Ashkin D, Auclair B, Berning SE, Jelliffe RW, Jaresko GS, Peloquin CA: Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int J Tuberc Lung Dis 2004;8:1360-1367. (Pubitemid 39611583)
50. Thee S, Detjen A, Quarcoo D, Wahn U, Magdorf K: Ethambutol in paediatric tuberculosis: Aspects of ethambutol serum concentration, efficacy and toxicity in children. Int J Tuber Lung Dis 2007;11:965-971. (Pubitemid 47425022)
51. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE: Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother 1999;43:568-572. (Pubitemid 29109520)
52. Jusko WJ, Gretch M: Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 1976;5:43-140.
53. Place VA, Peets EA, Buyske DA: Metabolic and special studies of ethambutol in normal volunteers and tuberculous patients. Ann NY Acad Sci 1966;135:775-795.
54. Lee CS, Gambertoglio JG, Brater DC, Benet LZ: Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 1977;22:615-621. (Pubitemid 8225579)
55. John, TR, Moore WM, Jeffries JE (eds): Children Are Different: Developmental Physiology, ed 2. columbus, Ross Laboratories, 1978.
56. Benkert K, Blaha H, Petersen KF, Schmid PC: Tagesprofile und Profilverlaufskontrollen von Ethambutol bei Kindern. Med Klin 1974;69:1808-1813.
57. Adcock JD, Hettig RA: Absorption, distribution and excretion of streptomycin. Arch Med Intern 1946;77:179-195.
58. Briedis DJ, Robson HG: Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother 1978;13:1042-1043.
59. Padovani EM, Pistolesi C, Fanos V, Messori A, Martini N: Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther 1993;20:167-173.
60. Assael BM, Parini R, Rusconi F, Cavanna G: Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr Res 1982;16:810-815. (Pubitemid 12018938)
61. Marik PE, Havlik I, Monteagudo FS, Lipman J: The pharmacokinetics of amikcacin in critically ill adult and paediatric patients: Comparison of once-versus twice-daily dosing regimens. J Antimicrob Chemother 1991;27(suppl C):81-89.
62. Beachler CW, Speer ME, Mason EO, Yow MD: Pharmacology of kanamycin in the newborn. South Med J 1982;75:301-305. (Pubitemid 12117744)
63. Howard JB, McCracken GH: Reappraisal of kanamycin usage in neonates. J Pediatr 1975;86:949-956.
64. Hieber JP, Nelson JD: Reevaluation of kanamycin dosage in infants and children. Antimicrob Agents Chemother 1976;9:899-902.
65. Herngren L, Boreus LO, Jalling B, Lagercrantz R: Pharmacokinetic aspects of streptomycin treatment of neonatal septicemia. Scand J Infect Dis 1977;9:301-308. (Pubitemid 8243409)
66. Bolme P, Eriksson M, Habte D, Paalzow L: Pharmacokinetics of streptomycin in Ethiopian children with tuberculosis of different nutritional status. Eur J Clin Pharmacol 1988;33:647-649. (Pubitemid 18063948)
67. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA: Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 2001;21:1037-1045. (Pubitemid 32807864)
68. Doluisio JT, Dittert LW, La Piana JC: Pharmacokinetics of kanamycin following intramuscular administration. J Pharmacokinet Biopharm1973;1:253-265.
69. Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE: Pharmacokinetics of amikacin in patients with normal or impaired renal function: Radioenzymatic acetylation assay. J Infect Dis 1976;134(suppl):S323-S330.
70. Eriksson M, Bolme P, Habte D, Paalzow L: INH and streptomycin in Ethiopian children with tuberculosis and different nutritional status. Acta Paediatr Scand 1988;77:890-894. (Pubitemid 19008622)
71. Hendricks MK, van der Bijl P, Parkin DP, Donald PR: Pharmacokinetics of amikacin in children with kwashiorkor. Ann Trop Paediatr 1995;15:295-298.
72. Forsyth NB, Botha JH, Hadley GP: A comparison of two amikacin dosing regimens in paediatric surgical patients. Ann Trop Paediatr 1997;17:253-261. (Pubitemid 27417184)
73. McCracken GH, Threlkeld N, Thomas ML: Intravenous administration of kanamycin and gentamicin in newborn infants. Pediatrics 1977;60:463-466. (Pubitemid 8208125)
74. Black HR, Griffith RS, Peabody AM: Absorption, excretion and metabolism of capreomycin in normal and diseased states. Ann NY Acad Sci 1966;135:974-982.
75. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA, Natarajan J, Maldonado S, Noel GJ: Levofloxacin pharmacokinetics in children. J Clin Pharmacol 2005;45:153-160. (Pubitemid 40490438)
76. Bethell DB, Day NP, Dung NM, McMullin C, Loan HT, Tam DT, Minh LT, Linh NT, Dung NQ, Vinh H, MacGowan AP, White LO, White NJ: Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob Agents Chemother 1996;40:2167-2172. (Pubitemid 26296266)
77. Capparelli EV, Reed MD, Bradley JS, Kearns GL, Jacobs RF, Damle BD, Blumer JL, Grasela DM: Pharmacokinetics of gatifloxacin in infants and children. Antimicrob Agents Chemother 2005;49:1106-1112. (Pubitemid 40327731)
78. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ: Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36:1086-1090.
79. Tachibana M, Tanaka M, Masubuchi Y, Horie T: Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab Dispos 2005;33:803-811. (Pubitemid 40686634)
80. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, Manns MP: Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002;50:259-265. (Pubitemid 34087942)
81. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R: Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612. (Pubitemid 43845020)
82. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE: Pharmacokinetics of paraaminosalicylic acid granules under four dosing conditions. Ann Pharmacother 2001;35:1332-1338. (Pubitemid 33042062)
83. Paser aminosalicylic acid granules delayed release (package insert). Princeton, Jacobus Pharmaceutical Company Inc, 1996.
84. Soderhjelm L: Serum para-aminosalicylic acid following oral ingestion in children. Tex Rep Biol Med 1949;7:471-479.
85. Way EL, Smith PK, Howie DL, Weiss R, Swanson R: The absorption, distribution, excretion and fate of para-aminosalicylic acid. J Pharmacol Exp Ther 1948;93:368-382.
86. Lehmann J: The role of the metabolism of paminosalicylic acid (PAS) in the treatment of tuberculosis: Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol. Scand J Respir Dis 1969;50:169-185.
87. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA: Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001;21:891-897. (Pubitemid 32747309)
88. Zitkova L, Tousek J: Pharmacokinetics of cycloserine and terizidone. Chemotherapy 1974;20:18-28.
89. Niemisto M: The influence of sustained release tablets effect on cycloserine concentration in serum. Scand J Respir Dis Suppl 1970;71:64-67.
90. Curci C: Pharmacological considerations on cycloserine. Scand J Respir Dis Suppl 1970;71:51-60.
91. Seromycin cycloserine capsule (package insert). Indianapolis, Eli Lilly & Co, 2005.
92. Conte JE, Barriere SL: Manual of Antibiotics and Infectious Diseases, ed 5. Philadelphia, Lea & Febiger, 1984.
93. Arbex MA, Varella MCL, de Siqueira HR, de Mello FA: Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. 2. Second line drugs. J Bras Pneumol 2010;36:641-656.
94. Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR, Sacchettini JC: Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 2007;204:73-78. (Pubitemid 46148758)
95. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA: Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food or antacids. Antimicrob Agents Chemother 2001;45:810-814. (Pubitemid 32182031)
96. Lee HW, Kim DW, Park JH, Kim SD, Lim MS, Phapale PB, Kim EH, Park SK, Yoon YR: Pharmacokinetics of prothionamide in patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13:1161-1166.
97. Conte JE, Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E: Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations. Antimicrob Agents Chemother 2000;44:1337-1341. (Pubitemid 30228315)
98. Peloquin CA, James GT, McCarthy E, Goble M: Pharmacokinetic evaluation of ethionamide suppositories. Pharmacotherapy 1991;11:359-363. 99 Jenner PJ, Smith SE: Plasma levels of ethionamide
99. Jenner PJ, Smith SE: Plasma levels of ethionamide and prothionamide in a volunteer following intravenous and oral dosages. Lepr Rev 1987;58:31-37. (Pubitemid 17073468)
100. Henderson MC, Siddens LK, Morre JT, Krueger SK, Williams DE: Metabolism of the antituberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Toxicol Appl Pharmacol 2008;233:420-427.
101. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN: Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 2002;51:236-243. (Pubitemid 34101340)
102. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA: Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis 2002;82:91-96. (Pubitemid 35155424)
103. Mathur A, Venkatesan K, Bharadwaj VP, Ramu G: Evaluation of effectiveness of clofazimine therapy. I. Monitoring of absorption of clofazimine from gastrointestinal tract. Indian J Lepr 1985;57:146-148. (Pubitemid 15030393)
104. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA: Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis 2004;84:365-373. (Pubitemid 39451903)
105. Mansfield RE: Tissue concentrations of clofazimine (B663) in man. Am J Trop Med Hyg 1974;23:1116-1119.
106. Schaad-Lanyi Z, Dieterle W, Dubois JP, Theobald W, Vischer W: Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobacter Dis 1987;55:9-15. (Pubitemid 17071023)
107. Abdel-Rahman SM, Kearns GL: An update on the oxazolidinone antibiotics. Pediatr Infect Dis J 1999;18:1101-1102.
108. Stalker DJ, Jungbluth GL: Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129-1140. (Pubitemid 37357649)
109. Kearns GL, Jungbluth GL, Abdel-Rahman SM, Hopkins NK, Welshman IR, Grzebyk RP, Bruss JB, van den Anker JN, Pediatric Pharmacology Research Unit Network: Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003;74:413-422. (Pubitemid 37357720)
110. Moellering RC: Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-142.
111. Jungbluth GL, Welshman IR, Hopkins NK: Linezolid pharmacokinetics in pediatric patients: An overview. Pediatr Infect Dis J 2003;22(suppl):S153-S157. (Pubitemid 37158763)
112. Ellard GA, Dickinson JM, Gammon PT, Mitchison DA: Serum concentrations and antituberculosis activity of thiacetazone. Tubercle 1974;55:41-54.
113. Jenner PJ, Ellard GA, Swai OB: A study of thiacetazone blood levels and urinary excretion in man, using high performance liquid chromatography. Lepr Rev 1984;55:121-128. (Pubitemid 14087198)
114. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT: Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy 1996;16:735-741. (Pubitemid 26322176)
115. François AA, Nishida CR, de Montellano PR, Phillips IR, Shephard EA: Human flavincontaining monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos 2009;37:178-186.
116. US National Institutes of Health clinical trials web site. www.clinicaltrials.gov/ct2/results?term=TMC207 (accessed April 11, 2010).
117. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227. (Pubitemid 40116230)
118. McNeeley DF: Update on the clinical development programme of TMC207 (R207910). Open Forum, London, UK, December 12-13, 2006. http://www. kaisernetwork.org/health-cast/uploaded-files/McNeeley,-David-(12-12)-TMC207.pdf.
119. Van Heeswijk R, Lachaert R, Leopold L, De Beule K, McNeeley D, Hoetelmans R: The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207 (poster PS-71358-11). 38th Union World Conf Lung Health, Cape Town, November 2007.
120. Matteelli A, Carvalho AC, Dooley KE, Kritski A: TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5:849-858.
121. Johnson TN, Tanner MS, Taylor CJ, Tucker GT: Enterocytic CYP3A4 in a paediatric population: Developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 2001;51:451-460. (Pubitemid 32852983)
122. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T: Expression of CYP3A in the human liver -evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-634. (Pubitemid 27308642)
123. Abdel-Rahman SM, Reed MD, Wells TG, Kearns GL: Considerations in the rational design and conduct of phase I/II pediatric clinical trials: Avoiding the problems and pitfalls. Clin Pharmacol Ther 2007;81:483-494. (Pubitemid 46454206)